Literature DB >> 2964201

Antagonists of the antidiuretic activity of vasopressin.

L B Kinter1, W F Huffman, F L Stassen.   

Abstract

Competitive antagonists of the antidiuretic (ADH) activity of vasopressin were first described some six years ago. When studied in vitro, ADH antagonists displace vasopressin from specific renal binding sites and antagonize, in a competitive fashion, vasopressin stimulation of adenylate cyclase and transepithelial water, salt, and urea fluxes. When studied in vivo, the ADH antagonists increase renal water excretion and antagonize, in a competitive fashion, the ADH activity of vasopressin. Marked species heterogeneity is apparent with ADH antagonists in vivo, and inconsistencies between in vitro and in vivo findings within the same species are reported. Other renal responses associated with administration of ADH antagonists include changes in renal hemodynamics and renal salt and urea excretion. The effects on salt excretion appear to be limited to those species in which vasopressin stimulation of epithelial salt reabsorption has been demonstrated. In summary, the role of vasopressin as the principal factor regulating renal water handling is supported by experience with ADH receptor antagonists. However, that experience also indicates the emerging significance of autocoids, and other synergistic factors, to affect ADH receptor/effector mechanisms and to modulate renal ADH responses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964201     DOI: 10.1152/ajprenal.1988.254.2.F165

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  The role of the gut in water balance.

Authors:  E M Gebruers
Journal:  Ir J Med Sci       Date:  1990-05       Impact factor: 1.568

Review 2.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

Review 3.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

Authors:  C Serradeil-Le Gal; C Lacour; G Valette; G Garcia; L Foulon; G Galindo; L Bankir; B Pouzet; G Guillon; C Barberis; D Chicot; S Jard; P Vilain; C Garcia; E Marty; D Raufaste; G Brossard; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  The location of the receptors involved in the human diuretic response to drinking an isotonic electrolyte solution.

Authors:  T B Crotty; E M Gebruers; W J Hall
Journal:  J Physiol       Date:  1992-05       Impact factor: 5.182

6.  Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; H Yamashita; T Chihara; H Miyamoto; S Nakamura; T Onogawa; T Yamashita; T Hosokawa; T Mori
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

7.  Modulation of the effect of arginine-vasopressin on water and ion transport in the newt early distal tubule and frog urinary bladder by V1-antagonists.

Authors:  O A Goncharevskaya; E I Shakhmatova; Y V Natochin
Journal:  Pflugers Arch       Date:  1995-10       Impact factor: 3.657

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.